Abeona Therapeutics (NASDAQ:ABEO) SVP Brendan O’malley Sells 4,826 Shares of Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) SVP Brendan O’malley sold 4,826 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $5.43, for a total value of $26,205.18. Following the transaction, the senior vice president directly owned 446,308 shares in the company, valued at $2,423,452.44. This trade represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abeona Therapeutics Price Performance

ABEO opened at $5.45 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.70 and a current ratio of 5.89. Abeona Therapeutics Inc. has a 52-week low of $4.00 and a 52-week high of $7.54. The stock has a market capitalization of $310.60 million, a PE ratio of 5.62 and a beta of 1.35. The stock’s 50 day moving average price is $5.37 and its 200-day moving average price is $5.16.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $4.57 million. On average, equities research analysts predict that Abeona Therapeutics Inc. will post -0.79 EPS for the current year.

More Abeona Therapeutics News

Here are the key news stories impacting Abeona Therapeutics this week:

• Positive Sentiment: Abeona previously reported quarterly EPS of -$0.30, beating estimates of -$0.33, and revenue of $8.72 million versus expectations of $4.57 million, which supports the bullish case for the stock.
• Positive Sentiment: Wall Street remains constructive overall, with two Buy ratings, an average Hold rating, and an average price target of $19.00, well above the current trading range.
• Neutral Sentiment: The company’s strong liquidity and low leverage, including a current ratio of 5.89 and debt-to-equity ratio of 0.03, provide financial flexibility.
• Negative Sentiment: CEO Vishwas Seshadri sold shares in multiple transactions on June 8 and June 9, reducing his stake, though the company said the sales were for tax withholding related to equity vesting. Article: CEO insider sale
• Negative Sentiment: CFO Joseph Walter Vazzano also sold shares on June 8 and June 9, including a larger Rule 10b5-1 transaction, adding to the insider-selling overhang. Article: CFO insider sale
• Negative Sentiment: SVP Brendan M. O’Malley and insider Madhav Vasanthavada also reported smaller sales, reinforcing a broader pattern of insider distribution that investors may view cautiously.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its stake in Abeona Therapeutics by 55.0% in the first quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company’s stock worth $13,888,000 after purchasing an additional 1,100,000 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in Abeona Therapeutics by 14.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after purchasing an additional 381,357 shares during the period. Vanguard Group Inc. grew its stake in Abeona Therapeutics by 3.8% in the third quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock worth $13,743,000 after purchasing an additional 95,878 shares during the period. Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,137,127 shares of the biopharmaceutical company’s stock worth $5,994,000 after acquiring an additional 9,996 shares in the last quarter. Finally, Kennedy Capital Management LLC boosted its holdings in Abeona Therapeutics by 56.4% in the third quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock worth $5,549,000 after acquiring an additional 378,860 shares in the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Wall Street Zen raised Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Stifel Nicolaus set a $17.00 price target on Abeona Therapeutics in a research note on Tuesday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.